Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
Avacta Life Sciences Ltd
Boehringer Ingelheim
Pfizer
Seagen Inc.
AstraZeneca
National Institutes of Health Clinical Center (CC)
Kivu Bioscience Inc.
University Health Network, Toronto
BeOne Medicines
University of Chicago
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Eli Lilly and Company
Debiopharm International SA
Novartis
University of Maryland, Baltimore